LCB-2122

Overview

LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin ( HY-15142A )-induced cardiomyocytes apoptosis with an IC 50 of 0.5 μM and prevent Imatinib ( HY-15463 )-induced apoptosis . LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase ( ACC ). LCB-2122 can reduce Doxorubicin -induced mitochondrial damage. LCB-2122 can be used for the research of heart failure.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Heart Disease | Products > Disease Areas > Heart Failure | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Acetyl-CoA Carboxylase | Products > Signaling Pathways > Nucleoside Antimetabolite/Analog | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > AMPK

Product Information

• Catalog No.: HY-180575
• CAS No.: 2210298-14-7
• Molecular Formula: C16H25ClN5O7P
• Molecular Weight: 465.83
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source